Current Headlines

  1. Ziarco Pharma Ltd - Phase 2a Psoriasis Study Initiated With Ziarco’s Lead Compound ZPL-389

    Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs against inflammatory skin disorders, recently announced that dosing has started in a Phase 2a proof of concept study in moderate to severe psoriasis with ZPL-389

  2. Enanta Pharmaceuticals To Present At The LEERINK Partners 5th Annual Global Healthcare Conference

    Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat format, or question and answer session with investors, at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016 at 9:15 a.m. ET

  3. Easily Measure Cancer Cell Death In A Co-Culture With KILR™ Assays From DiscoverX

    DiscoverX Corporation, a leading supplier of innovative cell-based assays and services for drug discovery and development, today announced the launch of the KILR Cytotoxicity Assay, a pioneering approach to accelerate the development of cancer immunotherapy drugs

  4. The Technology Evaluation Consortium™ Partners With Northeastern University To Evaluate A Process That Improves Delivery Of Poorly Soluble Drugs Using Nanoparticles

    The Technology Evaluation Consortium™ (TEC), managed by One Million Solutions in Health™, is managing an evaluation within the pharmaceutical and biotech industry of the Center for High-rate Nanomanufacturing's patented process to make insoluble compounds soluble

  5. Synergy Pharmaceuticals Files New Drug Application For Plecanatide In Chronic Idiopathic Constipation

    Synergy Pharmaceuticals Inc. recently announced the company has filed with the U.S. Food and Drug Administration (FDA) its first new drug application (NDA) for plecanatide in chronic idiopathic constipation (CIC)

  6. Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx® Cell Line Technology

    Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that Cerenis Therapeutics has advanced its leading clinical candidate, CER-001, into Phase III clinical studies across Europe and North America

  7. Crown Bioscience To Hold Symposium On Precision Medicine And Translating Oncology Drug Discovery Into Success In The Clinic

    Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, will be hosting a symposium at The Nucleus in Chesterford Research Park, UK, on Feb. 10, 2016

  8. Pharma Leader TGV-Laboratories Develops Breakthrough Drug To Fight ‘Antibiotic Apocalypse’

    A New York pharmaceutical company, TGV-Laboratories, has developed a groundbreaking drug that shows promise in treating a wide variety of antibiotic-resistant fungal and bacterial infections

  9. GeneOne Life Science And Inovio Pharmaceuticals To Collaborate On Zika Virus Vaccine Development

    GeneOne Life Science (KSE:011000) today announced the initiation of a collaborative research program with Inovio Pharmaceuticals (NASDAQ:INO) to test and advance a DNA-based vaccine for preventing and treating the emerging and virulent Zika virus infection.

  10. Accelerate Development Of Cancer Immunotherapy (iOnc) Drugs With New PathHunter® Checkpoint Assays From DiscoveRx

    DiscoveRx Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, announced today the expansion of its PathHunter cell-based assays portfolio with the release of PathHunter Checkpoint Assays